Alnylam Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Alnylam Pharmaceuticals, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on May 20, 2026, to elect directors, approve executive compensation, and ratify auditors.
NASDAQ
Alnylam Pharmaceuticals files an amendment to its proxy statement to clarify the voting requirements for a proposal regarding officer exculpation.
NASDAQ
Alnylam Pharmaceuticals announces its 2025 Annual Meeting of Stockholders, urging shareholders to vote on key proposals including the election of directors, approval of an amendment to the Restated Certificate of Incorporation, approval of the second amended and restated 2018 Stock Incentive Plan, an advisory vote on executive compensation, and ratification of the appointment of PricewaterhouseCoopers LLP as independent auditors.
NASDAQ
Alnylam Pharmaceuticals is set to hold its 2025 Annual Meeting of Stockholders virtually on May 8, 2025, with proposals including director elections, charter amendments, and executive compensation.
NASDAQ
Alnylam Pharmaceuticals announces its 2024 Annual Meeting of Stockholders to be held virtually on May 16, 2024, with voting open until May 15, 2024.
NASDAQ
Alnylam Pharmaceuticals announces its 2024 Annual Meeting of Stockholders to be held virtually on May 16, 2024, covering director elections, executive compensation, and auditor ratification.